AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2412521 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoamine oxidase inhibitor (N=9)
Number of subjects: 14
Study 2412521 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initial period and two-week washout)
Number of subjects: 14
Study 29067819 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive web-based intervention with 6 in-person group sessions over 12 months
Number of subjects: 73
Study 29067819 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive web-based intervention
Number of subjects: 73
Study 29067819 — intervention group
Group type: COMPARATOR
Intervention: Control group (customary care)
Number of subjects: 73
Study 28101658 — intervention group
Group type: EXPERIMENTAL
Intervention: Naso-intestinal tube
Number of subjects: 46
Study 25158287 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink (3 mg caffeine per kg body mass)
Number of subjects: 14
Study 25158287 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 14
Study 23458700 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based parent management training (PMT) for parents of children with conduct problems
Number of subjects: 57
Study 21600090 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose chemotherapy plus valproic acid (VPA)
Number of subjects: 41
Study 21600090 — intervention group
Group type: COMPARATOR
Intervention: Low dose chemotherapy regimen
Number of subjects: 41
Study 18329827 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication clinic only
Number of subjects: 100
Study 18329827 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication clinic plus BRENDA
Number of subjects: 100
Study 18329827 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication clinic plus cognitive behavioral therapy (CBT)
Number of subjects: 100
Study 18329827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17068818 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation (TSI)
Number of subjects: 32
Study 17068818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12511312 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose albuterol (15 mg/hr)
Number of subjects: 127
Study 12511312 — intervention group
Group type: COMPARATOR
Intervention: Usual-dose albuterol (7.5 mg/hr)
Number of subjects: 127
Study 10371571 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interleukin-2 (3 million IU/m2 twice daily for 5 days)
Number of subjects: 94
Study 10371571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous interleukin-2 (12 million IU/day for 5 days)
Number of subjects: 94
Study 10371571 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG interleukin-2 (2 million IU/m2 intravenous bolus every 2 months from week 2 to week 50)
Number of subjects: 94
Study 10371571 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine and didanosine alone (control group)
Number of subjects: 94
Study 8647056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 0
Study 8647056 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulins
Number of subjects: 0
Study 8647056 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 0
Study 1650528 — intervention group
Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy (cyclophosphamide, doxorubicin, and vincristine‐‐CAV) plus intrapleural bacillus Calmette‐Guerin (BCG) (n = 26)
Number of subjects: 52
Study 1650528 — intervention group
Group type: COMPARATOR
Intervention: adjuvant CAV alone (n = 26)
Number of subjects: 52
Study 1650528 — intervention group
Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy (CAV) plus intrapleural BCG
Number of subjects: 52
Study 1650528 — intervention group
Group type: COMPARATOR
Intervention: adjuvant CAV alone
Number of subjects: 52
Study 6868628 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous high‐voltage therapy with cobalt 60 (51 patients)
Number of subjects: 86
Study 6868628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra‐hard X‐rays from 17 MeV betatron (35 patients)
Number of subjects: 86
Study 6868628 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (Cobalt 60 and Betatron)
Number of subjects: 86
Study 29357820 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing a mix of plant oils and dairy fat (D)
Number of subjects: 88
Study 29357820 — intervention group
Group type: EXPERIMENTAL
Intervention: Only plant oils (P)
Number of subjects: 88
Study 29357820 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant oils supplemented with long-chain polyunsaturated fatty acids (PDHA)
Number of subjects: 88
Study 29357820 — intervention group
Group type: COMPARATOR
Intervention: Breastfed infants (BF)
Number of subjects: 88
Study 29357820 — intervention group
Group type: EXPERIMENTAL
Intervention: All formula groups (D, P, PDHA)
Number of subjects: 88
Study 26388169 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg oxantel pamoate
Number of subjects: 350
Study 26388169 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/kg oxantel pamoate
Number of subjects: 350
Study 26388169 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg oxantel pamoate
Number of subjects: 350
Study 26388169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 22590991 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg iron and 250 µg folate with or without 15 mg zinc
Number of subjects: 985
Study 21501249 — intervention group
Group type: EXPERIMENTAL
Intervention: small bowl and small scoop
Number of subjects: 54
Study 21501249 — intervention group
Group type: EXPERIMENTAL
Intervention: small bowl and large scoop
Number of subjects: 54
Study 21501249 — intervention group
Group type: EXPERIMENTAL
Intervention: large bowl and small scoop
Number of subjects: 54
Study 21501249 — intervention group
Group type: EXPERIMENTAL
Intervention: large bowl and large scoop
Number of subjects: 54
Study 20075647 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 28
Study 20075647 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 28
Study 17620127 — intervention group
Group type: COMPARATOR
Intervention: cis‐9, trans‐11 CLA (CONT)
Number of subjects: 0
Study 17620127 — intervention group
Group type: EXPERIMENTAL
Intervention: cis‐9, trans‐11 CLA (NAT)
Number of subjects: 0
Study 17620127 — intervention group
Group type: EXPERIMENTAL
Intervention: trans‐10, cis‐12 CLA and cis‐9, trans‐11 CLA (SYN)
Number of subjects: 0
Study 16290977 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified education program with follow-up phone call focusing on symptom management
Number of subjects: 36
Study 16290977 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 11902732 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN plus Ara‐C (5 million units/m2 IFN once per day and 20 mg/m2 Ara‐C for 10 days each month)
Number of subjects: 12
Study 11902732 — intervention group
Group type: COMPARATOR
Intervention: IFN alone (5 million units/m2 once per day)
Number of subjects: 12
Study 11902732 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN plus Ara‐C
Number of subjects: 12
Study 11902732 — intervention group
Group type: COMPARATOR
Intervention: IFN alone
Number of subjects: 12
Study 10615742 — intervention group
Group type: EXPERIMENTAL
Intervention: Utah Prepaid Mental Health Plan (UPMHP)
Number of subjects: 0
Study 10615742 — intervention group
Group type: COMPARATOR
Intervention: Contemporaneous control group
Number of subjects: 0
Study 8523000 — intervention group
Group type: EXPERIMENTAL
Intervention: Solcotrans drainage system
Number of subjects: 144
Study 8523000 — intervention group
Group type: COMPARATOR
Intervention: Hemovac disposable drainage system or inadequate drainage for autotransfusion
Number of subjects: 144
Study 1833896 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (0.5 mg/kg)
Number of subjects: 0
Study 1833896 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 0
Study 7180894 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-produced feedback
Number of subjects: 213
Study 7180894 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary sensory feedback
Number of subjects: 213
Study 7180894 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonretarded children)
Number of subjects: 213
Study 31814159 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Number of subjects: 0
Study 31814159 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance rituximab
Number of subjects: 0
Study 31814159 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0
Study 31814159 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide combined with rituximab
Number of subjects: 0
Study 31814159 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 30395745 — intervention group
Group type: EXPERIMENTAL
Intervention: Infographic
Number of subjects: 80
Study 30395745 — intervention group
Group type: EXPERIMENTAL
Intervention: Video
Number of subjects: 80
Study 28438210 — intervention group
Group type: EXPERIMENTAL
Intervention: BKPyV
Number of subjects: 266
Study 28438210 — intervention group
Group type: EXPERIMENTAL
Intervention: JCPyV
Number of subjects: 266
Study 28438210 — intervention group
Group type: EXPERIMENTAL
Intervention: BKPyV and JCPyV
Number of subjects: 266
Study 26028407 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 272
Study 26028407 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m² every 3 weeks)
Number of subjects: 272
Study 26028407 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 272
Study 26028407 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 272
Study 24150435 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Disc Replacement (TDR)
Number of subjects: 173
Study 24150435 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary Rehabilitation (MDR)
Number of subjects: 173
Study 20854196 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to DRV/r 800/100 mg once daily, either as monotherapy or with two NRTIs
Number of subjects: 256
Study 20854196 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of efavirenz or zidovudine
Number of subjects: 256
Study 20854196 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine screening of HIV-positive patients for vitamin D
Number of subjects: 256
Study 19017758 — intervention group
Group type: EXPERIMENTAL
Intervention: Detemir once daily and aspart before meals (n = 67)
Number of subjects: 130
Study 19017758 — intervention group
Group type: COMPARATOR
Intervention: Neutral protamine Hagedorn (NPH) and regular insulin twice daily (n = 63)
Number of subjects: 130
Study 19017758 — intervention group
Group type: EXPERIMENTAL
Intervention: Detemir/aspart group
Number of subjects: 130
Study 19017758 — intervention group
Group type: COMPARATOR
Intervention: NPH/regular group
Number of subjects: 130
Study 17523932 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite 400 microg daily during 4 weeks of TL01 therapy
Number of subjects: 13
Study 17523932 — intervention group
Group type: COMPARATOR
Intervention: Placebo during 4 weeks of TL01 therapy
Number of subjects: 13
Study 17523932 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite 400 microg daily
Number of subjects: 13
Study 15050199 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary fibromyalgia patients
Number of subjects: 41
Study 15050199 — intervention group
Group type: COMPARATOR
Intervention: Healthy women (control group)
Number of subjects: 41
Study 10746814 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 119
Study 10746814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 9545915 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer (resin-modified glass ionomer)
Number of subjects: 120
Study 9545915 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC Improved (resin-modified glass ionomer)
Number of subjects: 120
Study 9545915 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract (polyacid-modified resin composite)
Number of subjects: 120
Study 9545915 — intervention group
Group type: EXPERIMENTAL
Intervention: Compoglass (polyacid-modified resin composite)
Number of subjects: 120
Study 9545915 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomers
Number of subjects: 120
Study 1580920 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of parenteral antimicrobials (n=53 cases)
Number of subjects: 82
Study 1580920 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of parenteral therapy (n=11 cases)
Number of subjects: 82
Study 1580920 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=29 controls)
Number of subjects: 82
Study 3884180 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (SRT)
Number of subjects: 24
Study 2455107 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 2.5 mg b.i.d.
Number of subjects: 109
Study 2455107 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg b.i.d.
Number of subjects: 109
Study 2455107 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg b.i.d.
Number of subjects: 109
Study 2455107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 2455107 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (all doses)
Number of subjects: 109
Study 29843766 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass (S53P4)
Number of subjects: 50
Study 29843766 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone graft (ABG) with tricalcium phosphate
Number of subjects: 50
Study 28253938 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive standardized training
Number of subjects: 56
Study 28253938 — intervention group
Group type: COMPARATOR
Intervention: Minimal training
Number of subjects: 56
Study 26669302 — intervention group
Group type: EXPERIMENTAL
Intervention: Contoured sandals (n = 49)
Number of subjects: 150
Study 26669302 — intervention group
Group type: COMPARATOR
Intervention: Flat flip-flops (n = 50)
Number of subjects: 150
Study 26669302 — intervention group
Group type: COMPARATOR
Intervention: In-shoe orthoses (n = 51)
Number of subjects: 150
Study 23076002 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell hemoglobin-C disease (SCC) patients with proliferative stage III‐IV‐V retinopathy (group 3)
Number of subjects: 59
Study 23076002 — intervention group
Group type: COMPARATOR
Intervention: Sickle cell anemia (SCA) patients
Number of subjects: 59
Study 21392790 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple eradication therapy (n=16)
Number of subjects: 31
Study 21392790 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic therapy (n=15)
Number of subjects: 31
Study 18501583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal lidocaine 2% w/v
Number of subjects: 71
Study 18501583 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine 0.5% w/v
Number of subjects: 71
Study 18501583 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative motor blocking potency ratio
Number of subjects: 71
Study 16531421 — intervention group
Group type: EXPERIMENTAL
Intervention: KH‐3500 "accommodative" IOL
Number of subjects: 28
Study 16531421 — intervention group
Group type: COMPARATOR
Intervention: Softec1 IOL
Number of subjects: 28
Study 12972722 — intervention group
Group type: EXPERIMENTAL
Intervention: semi-standardized acupuncture (150 patients)
Number of subjects: 300
Study 12972722 — intervention group
Group type: EXPERIMENTAL
Intervention: standardized minimal acupuncture (75 patients)
Number of subjects: 300
Study 12972722 — intervention group
Group type: COMPARATOR
Intervention: no interval treatment for 12 weeks followed by semi-standardized acupuncture (75 patients, waiting list control)
Number of subjects: 300
Study 10746262 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 24
Study 10746262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8769387 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandostatin LAR (20 mg and 30 mg doses at 4-week intervals)
Number of subjects: 101
Study 8769387 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandostatin LAR
Number of subjects: 101
Study 1579579 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary polyunsaturated fatty acids (PUFA) intake, expressed as percentage of total kilocalories.
Number of subjects: 6250
Study 1579579 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary PUFA intake, expressed in absolute grams and ratios.
Number of subjects: 6250
Study 1579579 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (control).
Number of subjects: 6250
Study 4074196 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 15
Study 4074196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 4074196 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (open-label)
Number of subjects: 15
Study 4074196 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (all analyses)
Number of subjects: 15
Study 29498344 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated gut inflammation (GI) and permeability (GP) scores
Number of subjects: 539
Study 29498344 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated GP scores
Number of subjects: 539
Study 29498344 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher α-1 acid glycoprotein (AGP) levels
Number of subjects: 539
Study 29709127 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper patching
Number of subjects: 22
Study 29709127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 24126705 — intervention group
Group type: EXPERIMENTAL
Intervention: House of Education education program
Number of subjects: 502
Study 24126705 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 502
Study 23022248 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation
Number of subjects: 185
Study 23022248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 185
Study 20298993 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Percutaneous Coronary Intervention (PPCI)
Number of subjects: 6763
Study 20298993 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis (FL)
Number of subjects: 6763
Study 18555864 — intervention group
Group type: EXPERIMENTAL
Intervention: THA
Number of subjects: 210
Study 18555864 — intervention group
Group type: COMPARATOR
Intervention: THR
Number of subjects: 210
Study 15768425 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 100 microT(rms) 50 Hz MF exposure
Number of subjects: 18
Study 15768425 — intervention group
Group type: COMPARATOR
Intervention: Bright light (5000 lux) exposure
Number of subjects: 18
Study 15768425 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 18
Study 16737149 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (2 x 500 mg) with omeprazole (2 x 20 mg) and clarithromycin (2 x 500 mg)
Number of subjects: 0
Study 16737149 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (2 x 500 mg) with omeprazole (2 x 20 mg) and clarithromycin (2 x 500 mg)
Number of subjects: 0
Study 11074536 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon (3 mU s.c. 3 x weekly)
Number of subjects: 172
Study 11074536 — intervention group
Group type: COMPARATOR
Intervention: dexamethasone (20 mg/m2 p.o. each morning for 4 days)
Number of subjects: 172
Study 11074536 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon
Number of subjects: 172
Study 11074536 — intervention group
Group type: COMPARATOR
Intervention: dexamethasone
Number of subjects: 172
Study 8832444 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (2% initial target concentration, increments of 0.25%)
Number of subjects: 53
Study 8832444 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with 65% Nitrous Oxide (N2O)
Number of subjects: 53
Study 1413981 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic and possibly a beta-blocker or reserpine (active treatment group)
Number of subjects: 4
Study 1413981 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 4
Study 3911479 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular stanozolol, 50 mg on the preoperative day (n = 23)
Number of subjects: 60
Study 3911479 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral stanozolol, 10 mg/day for 2 weeks before and 1 week after operation (n = 11)
Number of subjects: 60
Study 3911479 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 26)
Number of subjects: 60
Study 31331587 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylsulfonylmethane (MSM) 6g daily
Number of subjects: 0
Study 31331587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30775426 — intervention group
Group type: EXPERIMENTAL
Intervention: roflumilast 500 ug daily
Number of subjects: 64
Study 30775426 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study 26912342 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation support consisting of US Center for Disease Control's Replicating Effective Programs strategy supplemented by external and internal implementation facilitation support.
Number of subjects: 765
Study 26912342 — intervention group
Group type: COMPARATOR
Intervention: Dissemination of materials plus technical assistance conference calls.
Number of subjects: 765
Study 25807670 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm saline mouth rinse (gargled 6 times daily)
Number of subjects: 160
Study 25807670 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mouth rinse instructions)
Number of subjects: 160
Study 23546629 — intervention group
Group type: EXPERIMENTAL
Intervention: Bufei Yishen Granule combined with Shufei Tie acupoint sticking therapy
Number of subjects: 244
Study 20884928 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucoadhesive disks (OraMoist) applied three times daily
Number of subjects: 27
Study 20884928 — intervention group
Group type: COMPARATOR
Intervention: Placebo mucoadhesive disks applied three times daily
Number of subjects: 27